# Ability Biotherapeutics

> Ability Biotherapeutics (also known as Ability Biologics) is a Montreal-based biotech founded in 2023 that engineers highly selective, immune-cell-modulating antibody therapeutics for cancer and autoimmune disease. Its AbiLeap discovery engine pairs continuously learning AI with one of the largest antibody-antigen interaction databases ever assembled to generate fully human, IgG-based multispecific antibodies that sense their environment and act only where intended - so-called logic-gated therapeutics. Backed by US$18M in seed capital led by Amplitude Ventures, the company is advancing a pipeline of immuno-oncology and autoimmune candidates toward preclinical readiness.

- **Founded:** 2023
- **Headquarters:** Montreal, Quebec, Canada
- **Founders:** Giles Day (Co-Founder & CEO), Jean-Philippe Bürckert (Co-Founder & Chief Technology Officer)
- **Team size:** ~25 employees (plans to triple headcount by 2028)
- **Products:** AbiLeap Discovery Engine, Leap 1121, Leap 1009, Leap 1030
- **Notable:** Closed US$18M in total seed funding led by Amplitude Ventures (2023-2024)., Unveiled the AbiLeap discovery platform in December 2023., Built one of the largest antibody-antigen interaction databases in the field, incorporating 5+ years of discovery data.

## Products & services

- **AbiLeap Discovery Engine** — A generative AI platform that combines massively parallel, continuously-learning machine learning with one of the largest antibody-antigen interaction databases ever built to design fully-human, IgG-based multispecific antibodies with exquisite selectivity, affinity and developability.
- **Leap 1121** — A first-in-class immune-cell-depleting antibody in preclinical development, targeting autoimmune and inflammatory skin diseases.
- **Leap 1009** — A Mesothelin x CD3 T cell engager with pH-sensitive binding, in discovery, aimed at solid tumors.
- **Leap 1030** — A TROP2 x CD3 T cell engager with pH-sensitive binding, in discovery, aimed at solid tumors.

## Achievements

- Closed US$18M in total seed funding led by Amplitude Ventures (2023-2024).
- Unveiled the AbiLeap discovery platform in December 2023.
- Built one of the largest antibody-antigen interaction databases in the field, incorporating 5+ years of discovery data.
- Advanced four biotherapeutic candidates across immuno-oncology and autoimmune disease.
- Expanded into Inspire Bio Innovations in Montreal in 2025 with plans to triple headcount by 2028.

## Latest updates

- **2025-06** — Published a feature on engineering smarter antibodies with a global team anchoring immunotherapy in Montreal.
- **2025-04** — Moved operations to the 6th floor of Phase 2 of Inspire Bio Innovations in Montreal, with plans to triple headcount by 2028.
- **2024-06** — Closed US$18M seed funding extension led by Amplitude Ventures to generate novel, highly-targeted immunomodulators.
- **2023-12** — Unveiled the AbiLeap discovery platform and raised initial US$12M seed round.

## Links

- Website: https://www.ability.bio
- LinkedIn: https://www.linkedin.com/company/ability-biologics

---

Profile page: https://yespress.io/ability-biotherapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-07